Therapeutic Products Programme
Holland Cross, Tower "B"
2nd Floor, 1600 Scott Street
Address Locator # 3102D1
OTTAWA, Ontario
K1A 1B6

July 24th, 2000

00-100521 - 582

Synergy Group of Canada Inc.
609 14 Street North West
CALGARY, Alberta
T2N 2A1

Dear Sir/Madam:

This refers to your firm's involvement in studies conducted in various centers, including the University of Calgary, the University of Ottawa, the University of Alberta and the University of Lethbridge, using a product or combination of products called Synergy for use in various disorders, including schizophrenia, autism, fibromyalgia.

The *Food and Drugs Act and Regulations* require that an Investigational New Drug Submission (IND) be filed with the Therapeutic Products Programme for evaluation prior to initiating a clinical trial. The review of the IND submission is subject to a 60-day default period, and a "No Objection Letter" would be issued should the proposed clinical trial be considered satisfactory. According to our records, no authorization has been obtained for any studies involving a product or group of products under the name of Synergy, or Synergy Quad Nutrient Program, or E.M.POWER+ powder drink, tablets or capsules.

In addition, information on your website at www.truehope.com promoting treatment with Synergy prior to obtaining authorization to market the product in Canada is in violation of the *Food and Drugs Act and Regulations*.

Information on the Canadian legislation and related documents are available on the Health Canada Website at www.hc-sc.gc.ca/hpb-dgps/therapeut.

.../2

Your cooperation in filing for an authorization to conduct clinical studies in Canada is requested.

Yours sincerely,

Original Signed By
Beth Pieterson

for/ Robert G. Peterson, M.D. PhD. MPH
A/Director General